Quality of life measurement in rosacea. Position statement of the European Academy of Dermatology and Venereology Task Forces on Quality of Life and Patient Oriented Outcomes and Acne, Rosacea and Hidradenitis Suppurativa
P. Chernyshov
(1)
,
A. Finlay
(2)
,
L. Tomas-Aragones
(3)
,
M. Steinhoff
(4, 5, 6, 7)
,
L. Manolache
(8)
,
N. Pustisek
(9)
,
C. Dessinioti
(10)
,
A. Svensson
(11)
,
S. Marron
(12)
,
A. Bewley
(13)
,
C. Salavastru
(14)
,
B. Dréno
(15)
,
A. Suru
(14)
,
D. Koumaki
(16)
,
D. Linder
(17)
,
A. Evers
(18)
,
D. Abeni
(19)
,
M. Augustin
(20)
,
S. Salek
(21)
,
A. Nassif
(22)
,
V. Bettoli
(23)
,
J. С. Szepietowski
(24)
,
C. Zouboulis
(25)
1
Université de Kiev
2 Cardiff University
3 University of Zaragoza - Universidad de Zaragoza [Zaragoza]
4 Hamad Medical Corporation [Doha, Qatar]
5 Weill Cornell Medicine [Qatar]
6 Qatar University
7 Weill Cornell Medicine [Cornell University]
8 Dali Medical
9 Children’s Hospital Srebrnjak [Zagreb, Croatia]
10 University of Athens Medical School [Athens]
11 Skane University Hospital [Malmo]
12 Royo Villanova Hospital
13 Whipps Cross University Hospital
14 UMPCD - University of Medicine and Pharmacy “Carol Davila” Bucharest
15 INCIT - Immunology and New Concepts in ImmunoTherapy
16 UOC - University of Crete [Heraklion]
17 Medical University of Graz
18 Leiden University
19 IRCCS - Istituto di Ricovero e Cura a Carattere Scientifico
20 UKE - Universitaetsklinikum Hamburg-Eppendorf = University Medical Center Hamburg-Eppendorf [Hamburg]
21 UH - University of Hertfordshire [Hatfield]
22 IP - Institut Pasteur [Paris]
23 UniFE - Università degli Studi di Ferrara = University of Ferrara
24 Wrocław Medical University
25 MHB Theodor Fontane - Medizinische Hochschule Brandenburg Theodor Fontane / Brandenburg Medical School Theodor-Fontane
2 Cardiff University
3 University of Zaragoza - Universidad de Zaragoza [Zaragoza]
4 Hamad Medical Corporation [Doha, Qatar]
5 Weill Cornell Medicine [Qatar]
6 Qatar University
7 Weill Cornell Medicine [Cornell University]
8 Dali Medical
9 Children’s Hospital Srebrnjak [Zagreb, Croatia]
10 University of Athens Medical School [Athens]
11 Skane University Hospital [Malmo]
12 Royo Villanova Hospital
13 Whipps Cross University Hospital
14 UMPCD - University of Medicine and Pharmacy “Carol Davila” Bucharest
15 INCIT - Immunology and New Concepts in ImmunoTherapy
16 UOC - University of Crete [Heraklion]
17 Medical University of Graz
18 Leiden University
19 IRCCS - Istituto di Ricovero e Cura a Carattere Scientifico
20 UKE - Universitaetsklinikum Hamburg-Eppendorf = University Medical Center Hamburg-Eppendorf [Hamburg]
21 UH - University of Hertfordshire [Hatfield]
22 IP - Institut Pasteur [Paris]
23 UniFE - Università degli Studi di Ferrara = University of Ferrara
24 Wrocław Medical University
25 MHB Theodor Fontane - Medizinische Hochschule Brandenburg Theodor Fontane / Brandenburg Medical School Theodor-Fontane
C. Dessinioti
- Function : Author
- PersonId : 1224497
- ORCID : 0000-0002-4832-3410
A. Svensson
- Function : Author
- PersonId : 1224498
- ORCID : 0000-0002-2821-7418
A. Bewley
- Function : Author
- PersonId : 1224499
- ORCID : 0000-0003-1195-0290
D. Koumaki
- Function : Author
- PersonId : 1224500
- ORCID : 0000-0001-7074-2374
D. Linder
- Function : Author
- PersonId : 766888
- ORCID : 0000-0002-0305-3146
M. Augustin
- Function : Author
- PersonId : 1224501
- ORCID : 0000-0002-4026-8728
S. Salek
- Function : Author
- PersonId : 1224502
- ORCID : 0000-0002-4612-5699
V. Bettoli
- Function : Author
- PersonId : 1224503
- ORCID : 0000-0002-2760-4600
J. С. Szepietowski
- Function : Author
- PersonId : 800839
- ORCID : 0000-0003-0766-6342
C. Zouboulis
- Function : Author
- PersonId : 1224504
- ORCID : 0000-0003-1646-2608
Abstract
The European Academy of Dermatology and Venereology (EADV) Task Forces (TFs) on Quality of Life (QoL) and Patient-Oriented Outcomes and Acne, Rosacea and Hidradenitis Suppurativa (ARHS) do not recommend the use of any generic instrument as a single method of Health Related (HR) QoL assessment in rosacea, except when comparing quimp (quality of life impairment) in rosacea patients with that in other non-dermatologic skin diseases and/or healthy controls. The EADV TFs on QoL and Patient-Oriented Outcomes and ARHS recommend the use of the dermatology-specific HRQoL instrument the Dermatology Life Quality Index (DLQI) and the rosacea-specific HRQoL instrument RosaQoL in rosacea patients. The DLQI minimal clinically important difference may be used as a marker of clinical efficacy of the treatment and DLQI score banding of 0 or 1 corresponding to no effect on patients' HRQoL could be an important treatment goal. This information may be added to consensuses and guidelines for rosacea.